Revenue grew 4.7% organically to $318.2m and adjusted operating profit rose 16.4% to $73.2m, with margins and EPS significantly improved. The sale of the pharma business and a new share buyback strengthened the balance sheet, and full-year guidance remains confident despite macro risks.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.